QQQ   444.35 (-0.11%)
AAPL   171.29 (-1.17%)
MSFT   419.96 (-0.35%)
META   486.13 (-1.57%)
GOOGL   150.76 (-0.07%)
AMZN   180.25 (+0.23%)
TSLA   177.93 (-1.06%)
NVDA   907.75 (+0.58%)
NIO   4.61 (-1.28%)
AMD   182.08 (+1.39%)
BABA   72.48 (+1.24%)
T   17.62 (+0.40%)
F   13.22 (+1.23%)
MU   118.11 (-0.86%)
CGC   9.94 (+4.08%)
GE   175.56 (-2.53%)
DIS   122.62 (+1.36%)
AMC   3.69 (-14.98%)
PFE   27.96 (+0.65%)
PYPL   67.52 (+1.43%)
XOM   115.72 (+0.65%)
QQQ   444.35 (-0.11%)
AAPL   171.29 (-1.17%)
MSFT   419.96 (-0.35%)
META   486.13 (-1.57%)
GOOGL   150.76 (-0.07%)
AMZN   180.25 (+0.23%)
TSLA   177.93 (-1.06%)
NVDA   907.75 (+0.58%)
NIO   4.61 (-1.28%)
AMD   182.08 (+1.39%)
BABA   72.48 (+1.24%)
T   17.62 (+0.40%)
F   13.22 (+1.23%)
MU   118.11 (-0.86%)
CGC   9.94 (+4.08%)
GE   175.56 (-2.53%)
DIS   122.62 (+1.36%)
AMC   3.69 (-14.98%)
PFE   27.96 (+0.65%)
PYPL   67.52 (+1.43%)
XOM   115.72 (+0.65%)
QQQ   444.35 (-0.11%)
AAPL   171.29 (-1.17%)
MSFT   419.96 (-0.35%)
META   486.13 (-1.57%)
GOOGL   150.76 (-0.07%)
AMZN   180.25 (+0.23%)
TSLA   177.93 (-1.06%)
NVDA   907.75 (+0.58%)
NIO   4.61 (-1.28%)
AMD   182.08 (+1.39%)
BABA   72.48 (+1.24%)
T   17.62 (+0.40%)
F   13.22 (+1.23%)
MU   118.11 (-0.86%)
CGC   9.94 (+4.08%)
GE   175.56 (-2.53%)
DIS   122.62 (+1.36%)
AMC   3.69 (-14.98%)
PFE   27.96 (+0.65%)
PYPL   67.52 (+1.43%)
XOM   115.72 (+0.65%)
QQQ   444.35 (-0.11%)
AAPL   171.29 (-1.17%)
MSFT   419.96 (-0.35%)
META   486.13 (-1.57%)
GOOGL   150.76 (-0.07%)
AMZN   180.25 (+0.23%)
TSLA   177.93 (-1.06%)
NVDA   907.75 (+0.58%)
NIO   4.61 (-1.28%)
AMD   182.08 (+1.39%)
BABA   72.48 (+1.24%)
T   17.62 (+0.40%)
F   13.22 (+1.23%)
MU   118.11 (-0.86%)
CGC   9.94 (+4.08%)
GE   175.56 (-2.53%)
DIS   122.62 (+1.36%)
AMC   3.69 (-14.98%)
PFE   27.96 (+0.65%)
PYPL   67.52 (+1.43%)
XOM   115.72 (+0.65%)
NASDAQ:CLRB

Cellectar Biosciences (CLRB) Stock Price, News & Analysis

$3.91
+0.27 (+7.42%)
(As of 12:46 PM ET)
Today's Range
$3.79
$3.92
50-Day Range
$3.28
$4.24
52-Week Range
$1.30
$4.45
Volume
715,945 shs
Average Volume
1.86 million shs
Market Capitalization
$48.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Cellectar Biosciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
313.4% Upside
$16.00 Price Target
Short Interest
Healthy
16.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.73mentions of Cellectar Biosciences in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.02) to ($2.23) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.37 out of 5 stars

Medical Sector

572nd out of 939 stocks

Pharmaceutical Preparations Industry

266th out of 433 stocks

CLRB stock logo

About Cellectar Biosciences Stock (NASDAQ:CLRB)

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

CLRB Stock Price History

CLRB Stock News Headlines

Q4 2023 Cellectar Biosciences Inc Earnings Call
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Earnings Preview For Cellectar Biosciences
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Cellectar Biosciences Inc
Cellectar Biosciences Inc (CLRB)
See More Headlines
Receive CLRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2021
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CLRB
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.00
High Stock Price Target
$20.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+283.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-28,600,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.51 per share

Miscellaneous

Free Float
11,723,000
Market Cap
$48.05 million
Optionable
Optionable
Beta
0.93
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

CLRB Stock Analysis - Frequently Asked Questions

Should I buy or sell Cellectar Biosciences stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLRB shares.
View CLRB analyst ratings
or view top-rated stocks.

What is Cellectar Biosciences' stock price target for 2024?

2 analysts have issued 1-year price objectives for Cellectar Biosciences' shares. Their CLRB share price targets range from $12.00 to $20.00. On average, they anticipate the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 313.4% from the stock's current price.
View analysts price targets for CLRB
or view top-rated stocks among Wall Street analysts.

How have CLRB shares performed in 2024?

Cellectar Biosciences' stock was trading at $2.77 at the start of the year. Since then, CLRB shares have increased by 39.7% and is now trading at $3.87.
View the best growth stocks for 2024 here
.

Are investors shorting Cellectar Biosciences?

Cellectar Biosciences saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 1,880,000 shares, a decline of 6.5% from the February 29th total of 2,010,000 shares. Based on an average trading volume of 1,760,000 shares, the short-interest ratio is presently 1.1 days. Currently, 16.9% of the company's stock are short sold.
View Cellectar Biosciences' Short Interest
.

When is Cellectar Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CLRB earnings forecast
.

How were Cellectar Biosciences' earnings last quarter?

Cellectar Biosciences, Inc. (NASDAQ:CLRB) posted its earnings results on Sunday, November, 7th. The biopharmaceutical company reported ($1.00) earnings per share for the quarter, beating analysts' consensus estimates of ($1.10) by $0.10.

When did Cellectar Biosciences' stock split?

Cellectar Biosciences shares reverse split on the morning of Friday, July 22nd 2022. The 1-10 reverse split was announced on Friday, July 22nd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Cellectar Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), Bombardier, Inc. Class B (BBD.B), Bonavista Energy Co. (BNP.TO) (BNP) and Hudbay Minerals (HBM).

Who are Cellectar Biosciences' major shareholders?

Cellectar Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include AIGH Capital Management LLC (15.58%), ADAR1 Capital Management LLC (11.21%), Nantahala Capital Management LLC (10.99%), Worth Venture Partners LLC (5.65%), Vanguard Group Inc. (3.93%) and Vanguard Group Inc. (3.93%).
View institutional ownership trends
.

How do I buy shares of Cellectar Biosciences?

Shares of CLRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CLRB) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners